Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions (ORBIT II)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cardiovascular Systems Inc
ClinicalTrials.gov Identifier:
NCT01092416
First received: March 23, 2010
Last updated: August 10, 2016
Last verified: August 2016

March 23, 2010
August 10, 2016
May 2010
January 2013   (final data collection date for primary outcome measure)
  • Primary Safety Endpoint: 30-Day Freedom From Major Adverse Cardiac Events (MACE) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

    OAS safety was measured by a composite of MACE at 30-days post procedure. MACE is composed of:

    • Cardiac death.
    • MI - defined as a CK-MB level > 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave.
    • TVR - defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure.
  • Primary Efficacy Endpoint: Procedural Success [ Time Frame: Participants were followed from baseline procedure through the duration of hospital stay, an average of 33.6 hours. ] [ Designated as safety issue: Yes ]
    Procedural success was defined as success in facilitating stent delivery with a residual stenosis of <50% and without the occurrence of an in-hospital MACE in de novo, severely calcified coronary lesions.
Major Adverse Cardic Event (MACE) [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

30-day MACE is composed of:

  • Cardiac death.
  • MI - defined as a CK-MB level > 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave.
  • TVR - defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure.
Complete list of historical versions of study NCT01092416 on ClinicalTrials.gov Archive Site
  • Angiographic Success [ Time Frame: Baseline procedure, with a mean total procedure time of 52.5 minutes. ] [ Designated as safety issue: Yes ]
    Angiographic success was defined as success in facilitating stent delivery with <50% residual stenosis and without severe angiographic complications.
  • Severe Angiographic Complications [ Time Frame: Baseline procedure, with a mean total procedure time of 52.5 minutes. ] [ Designated as safety issue: Yes ]
    Severe angiographic complications were defined as severe dissection (Type C to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow.
  • 12-Month Freedom From Major Adverse Cardiac Events (MACE) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    The safety of the OAS was measured for the secondary safety endpoint consisting of a composite of freedom from MACE through 12 months of follow-up.
  • Angiographic Success [ Time Frame: Preodecure ] [ Designated as safety issue: No ]
    Angiographic success is defined as success in facilitating stent delivery with <50% residual stenosis and without serious angiographic complications.
  • Severe Angiographic Complications [ Time Frame: Procedure ] [ Designated as safety issue: Yes ]
    Severe angiographic complications are defined as severe dissection (Type C to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow.
  • 12-Month MACE [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    See MACE definition in the primary outcome
Not Provided
Not Provided
 
Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions
Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360°® Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II)
This is a prospective, single-arm, multi-center study to evaluate the safety and performance of the OAS in treating de novo, severely calcified coronary lesions in adult subjects. Study is going to enroll up to 429 subjects in up to 50 U.S. study sites. The primary safety endpoint is 30-day MACE and primary efficacy endpoint is procedural success. All subjects will be treated with the orbital atherectomy system and adjunctive stent. All subjects will be followed in clinic at 30 days. Additionally, all subjects will have an annual phone call or clinical follow up at each anniversary until study is closed.
Not Provided
Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Coronary Artery Disease
Device: Diamondback 360 Orbital Atherectomy System
Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
443
January 2016
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must be 18 or older.
  • Subjects must have a clinical indication for coronary intervention.
  • CK and CK-MB must be less than or equal to the upper limit of lab normal value within 8 hours prior to the procedure.
  • The target lesion must be a de novo coronary lesion that has not been previously treated with any interventional procedure.
  • The target vessel must be a native coronary artery with a stenosis of >= 70% and < 100%.
  • The target vessel reference diameter must be >= 2.5mm and <= 4.0 mm.
  • The lesion length must not exceed 40 mm.
  • The target vessel must have a TIMI flow 3 at baseline.
  • The target lesion must have evidence of severe calcium deposit at the lesion site based on the protocol criterion.
  • The lesion must be crossable with the study guide wire.

Exclusion Criteria:

  • Inability to understand the study or a history of non-compliance with medical advice.
  • Unwilling or unable to sign the ORBIT II Informed Consent Form (ICF).
  • History of any cognitive or mental health status that would interfere with study participation.
  • Currently enrolled in any other pre-approval investigational study (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.).
  • Female subjects who are pregnant or planning to become pregnant within the study period.
  • Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel without adequate alternative medications.
  • Known sensitivity to contrast media, which cannot be adequately pre-medicated.
  • Diagnosed with chronic renal failure or has a serum creatinine level >2.5 mg/dl.
  • Experienced acute MI (STEMI or non-STEMI: CK and CK-MB greater than 1 times the upper limit of lab normal) within 30 days prior to index procedure.
  • History of major cardiovascular intervention within 30 days.
  • Evidence of current (within 6 months) left ventricular ejection fraction ≤ 25%.
  • NYHA class III or IV heart failure.
  • History of a stroke or transient ischemic attack (TIA) within 6 months.
  • Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months.
  • History of bleeding diathesis or coagulopathy or intention to refuse blood transfusion if one should become necessary.
  • Concurrent medical condition with a life expectancy of less than 12 months.
  • History of immune deficiency.
  • Uncontrolled insulin dependent diabetes.
  • Evidence of active infections on the day of the index procedure.
  • Subject has planned cardiovascular intervention within 60-days post index procedure.
  • Subject is not an acceptable candidate for emergent coronary artery bypass surgery.
  • Subject with known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin and sodium hydroxide.
  • Subject with 3 lesions requiring intervention.
  • Subject with 2 lesions unless the treatment of the lesions is staged. The non target lesion must first be treated at least 12 hours prior to the index procedure. The subject's CK and CK-MB must be less than or equal to one times the upper limit of the lab normal value 12 ± 2 hours post procedure and there were no procedural complications during the first lesion intervention.
  • Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or LIMA/RIMA bypass.
  • Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate or on-line QCA.
  • Target vessel has angiographically visible or suspected thrombus.
  • Target vessel has a stent from previous PCI.
  • Target vessel is excessively tortuous.
  • Target lesion is an ostial location (within 5 mm of ostium) or an unprotected left main lesion.
  • Target lesion is a bifurcation.
  • Target lesion has a ≥ 1.5 mm side branch.
  • Angiographic evidence of a dissection prior to OAS treatment.
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01092416
ORBIT II
Yes
Not Provided
Not Provided
Cardiovascular Systems Inc
Cardiovascular Systems Inc
Not Provided
Principal Investigator: Jeffrey Chambers, MD Metropolitan Cardiology Consutants
Cardiovascular Systems Inc
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP